<DOC>
	<DOCNO>NCT00367484</DOCNO>
	<brief_summary>The objective study : - comparison incidence time course development neutralize antibody ( NAbs ) Rebif 48 week therapy , historical data Serono clinical trial database assess safety tolerability Rebif®</brief_summary>
	<brief_title>Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a ( Rebif® ) Using Clone 484-39 In Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Have multiple sclerosis ( MS ) two relapse past two year eligible interferon therapy . Be 18 60 year age , inclusive . Have give write informed consent , prior study related procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Be willing able follow study procedure duration study . Have Expanded Disability Scale Score ( EDSS ) less 6.0 If female , must either 1. post menopausal surgically sterilise ; 2. use hormonal contraceptive , intra uterine device , diaphragm spermicide , condom spermicide , duration study ; 3. neither pregnant breast feeding . Confirmation subject pregnant must establish negative SERUM human Chorionic Gonadotrophin ( hCG ) pregnancy test 28 7 day Study Day 0.Urine pregnancy test must do serum hCG pregnancy test perform 7 day Study Day 0 . A pregnancy test require subject post menopausal surgically sterilise . Prior Interferon beta therapy ( either beta1b beta1a ) . Major medical psychiatric illness opinion investigator create undue risk subject could affect compliance study protocol . Significant immunosuppressive therapy within 6 month prior enrolment . Known history hypersensitivity natural recombinant interferon beta , human serum albumin , component formulation . Epilepsy history seizure adequately control treatment . Have great Grade 1 toxicity liver function test ( Aspartate Transaminase ( AST ) , Alanine Transaminase ( ALT ) , GammaGlutamyl Transferase ( GGT ) total bilirubin ) Screening visit Have significant leukopenia ( great Grade 1 toxicity total white blood cell count lymphopenia ) Screening visit Have treatment oral systemic corticosteroid Adrenocorticotrophic hormone ( ACTH ) within 1 month Screening visit screen visit study day 0 . Cytokine anticytokine therapy within 3 month prior Screening visit screen visit study day 0 . Use immunomodulatory immunosuppressive therapy ( include limit cyclophosphamide , cyclosporin , methotrexate , azathioprine , linomide ) within 6 month prior Screening visit screen visit study day 0 . Have take intravenous immunoglobulin glatiramer acetate mitoxantrone investigational drug experimental procedure within 3 month prior Screening visit screen visit study day 0 . Prior use cladribine receive total lymphoid irradiation . Presence systemic disease might interfere patient safety , compliance evaluation condition study ( e.g . poorly control insulindependent diabetes , Lyme disease , clinically significant cardiac disease , human immunodeficiency virus ( HIV ) , human Tlymphotrophic virus 1 ( HTLV1 ) ) . Other concurrent systemic disorder incompatible study ( Investigator 's discretion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>